Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-08-04
2009-08-18
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S422000, C514S447000
Reexamination Certificate
active
07576117
ABSTRACT:
A medicine containing, as an active ingredient, a cyclic amine derivative represented by the following formula (I),a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1to C6alkyl addition salt thereof. The medicine has an action for treating or preventing diseases in which CCR3 participates, such as asthma and allergic rhinitis.
REFERENCES:
patent: 4443461 (1984-04-01), Ward
patent: 6166015 (2000-12-01), Rogers et al.
patent: 6362177 (2002-03-01), Shiota et al.
patent: 6410566 (2002-06-01), Shiota et al.
patent: 6451842 (2002-09-01), Shiota et al.
patent: 1279668 (2001-01-01), None
patent: 217286 (1987-04-01), None
patent: 903349 (1999-03-01), None
patent: 1 201 239 (2002-05-01), None
patent: 2106108 (1983-04-01), None
patent: WO 97/24325 (1997-07-01), None
patent: WO 97/40051 (1997-10-01), None
patent: WO 97/44329 (1997-11-01), None
patent: WO 98/02151 (1998-01-01), None
patent: WO 98/04554 (1998-02-01), None
patent: WO 98/06703 (1998-02-01), None
patent: WO 98/25604 (1998-06-01), None
patent: WO 98/25605 (1998-06-01), None
patent: WO 98/25617 (1998-06-01), None
patent: WO 98/27815 (1998-07-01), None
patent: WO 98/30218 (1998-07-01), None
patent: WO 98/31364 (1998-07-01), None
patent: WO 98/38167 (1998-09-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 99/01127 (1999-01-01), None
patent: 99/25686 (1999-05-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 00/9377 (2000-02-01), None
patent: WO 00/31032 (2000-06-01), None
patent: WO 00/31033 (2000-06-01), None
patent: WO 00/35449 (2000-06-01), None
patent: WO 00/35451 (2000-06-01), None
patent: WO 00/69815 (2000-11-01), None
Frade et al. “The amino-terminal Domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection,” J. Chinical Investigation, 1997, vol. 100, No. 3, pp. 497-502.
Khalid et al, “N, N′-disubstituted L-isoglutamines as novel cancer chemotherapeutic agents”, Drugs Exp. Clin. Res. (1987), vol. 13, Suppl. 1, p. 57-60.
International Search Report.
N. Zimmerman, et al. “Polymorphisms in the human CC chemokine receptor-3 gene”Biochimica et Biophysica Acta. Gene Structure and Expression, Elsevier Amsterdam, NL, vol. 1442, No. 2-3, Nov. 8, 1998, pp. 170-176, XP004275252
H. Choe, et al. “The Beta-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates”Cell, Cell Press, Cambridge MA, US, vol. 85, No. 7, Jun. 28, 1996, pp. 1135-1148.
Chen, et al. “CCR3 and CCR5 are co-receptors for HIV-infection of microglia”Nature, Macmillan Journals Ltd., London, GB, vol. 385, No. 6617, Feb. 13, 1997, pp. 645-649, XP002107165.
Krishna Vaddi, “Chemokine Facts Book, Acad. Press,” 1997 San Diego, CA, pp. 1-2, 10-37, 86-130, 135-137, 142-143, 158-164.
Franklin H. Epstein, M.D, Luster, D. Andrew, “Chemokines—Chemotactic Cytokines that Mediate Inflammation”, The New England Journal of Medicine (Feb. 12, 1998), vol. 338 pp. 436-445.
Marco Baggiolini “Chemokines and leukocyte traffic” Nature vol. 392 pp. 565-568 Apr. 9, 1998.
Joseph Hesselgesser “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor” The Journal of Biological Chemistry vol. 273, No. 25, Jun. 19, 1998 pp. 15687-15692.
European Communication Nov. 29 , 2002.
Bright, Colin, et al. Identification of a Non- Peptidic Rantes Antagonist, vol. 1, No. 1, Bioorganic & Medicinal Chemistry Letters, 1998 pp. 771-774.
Ward, G. Stephen, et al., “Chemokines: understanding their role in T-lymphocyte biology”, Biochem. J. (1998) 333, pp. 457-470.
European Communication Sep. 17, 2003.
Rapport, Carol A., et al., “Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine Receptor (CCR5) for Rantes, MIP-1β, and MIP-1α,” The Journal of Biological Chemistry, The American Society for Biochemistry and Molecular Biology, Inc., 1996, pp. 17161-17166, vol. 271, No. 29, Issue of Jul. 19th, USA.
Murai, Masako, et al., “Active participation of CCR5+CD8+T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease,” The Journal of Clinical Investigations, Jul. 1999, pp. 49-57, vol. 104, No. 1.
Balashov, Konstantin E., “CCR5+and CXCR3+T cells are Increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions,” Proc. Natl. Acad. Sci., Jun. 1999, pp. 6873-6878, vol. 90, USA.
Bradley, Linda, et al., The Journal of Immunology, vol. 162(5), pp. 2511-2520, Mar. 4, 1999.
Zimmerman, N. et al., “Polymorphisms in the human CC chermokine receptor-3 gene”, Biochimica et Biophysica Acta, 1998, pp. 170-176, vol. 1442, Elsevier Science B.V.
Kamimura Takashi
Muroga Yumiko
Nakanishi Akinobu
Shiota Tatsuki
Sudoh Masaki
Sughrue & Mion, PLLC
Teijin Limited
Wang Shengjun
LandOfFree
Cyclic amine CCR3 antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic amine CCR3 antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic amine CCR3 antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079657